Company profile for Nuvation Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Nuvation Bio, is a privately-held biopharmaceutical company currently operating in stealth mode that is focused on the development of next generation therapies that will target the foremost unmet needs in oncology. Nuvation Bio's proprietary portfolio includes seven novel and mechanistically distinct oncology programs, each with multiple drug development candidates. Nuvation Bio was founded in 2018 by industry veteran David Hu...
Nuvation Bio, is a privately-held biopharmaceutical company currently operating in stealth mode that is focused on the development of next generation therapies that will target the foremost unmet needs in oncology. Nuvation Bio's proprietary portfolio includes seven novel and mechanistically distinct oncology programs, each with multiple drug development candidates. Nuvation Bio was founded in 2018 by industry veteran David Hung, M.D., who previously founded and served as President and Chief Executive Officer of Medivation. Nuvation Bio has offices in New York and San Francisco.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1500 Broadway Suite 1401 New York, NY 10036
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251126713664/en/Nuvation-Bio-to-Participate-in-Upcoming-Investor-Conferences

BUSINESSWIRE
26 Nov 2025

https://investors.nuvationbio.com/news/news-details/2025/Nuvation-Bio-Enrolls-First-Patient-in-Global-Randomized-Study-of-Safusidenib-for-Maintenance-Treatment-of-High-Grade-IDH1-Mutant-Glioma/default.aspx

PRESS RELEASE
04 Nov 2025

https://www.businesswire.com/news/home/20251103661962/en/Nuvation-Bio-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update

BUSINESSWIRE
03 Nov 2025

https://www.businesswire.com/news/home/20251030576078/en/Nuvation-Bio-to-Participate-in-Upcoming-Investor-Conferences

BUSINESSWIRE
30 Oct 2025

https://www.businesswire.com/news/home/20251023640173/en/Nuvation-Bio-Enrolls-First-Patient-in-Global-Randomized-Study-of-Safusidenib-for-Maintenance-Treatment-of-High-Grade-IDH1-Mutant-Glioma

BUSINESSWIRE
23 Oct 2025

https://www.businesswire.com/news/home/20251020517066/en/Nuvation-Bio-to-Report-Third-Quarter-2025-Financial-Results-and-Provide-Business-Update-on-November-3-2025

BUSINESSWIRE
20 Oct 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty